BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37777577)

  • 1. Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: an analysis of the IGCCCG Update database.
    Lauritsen J; Sauvé N; Tryakin A; Jiang DM; Huddart R; Heng DYC; Terbuch A; Winquist E; Chovanec M; Hentrich M; Fankhauser CD; Shamash J; Del Muro XG; Vaughn D; Heidenreich A; Sternberg CN; Sweeney C; Necchi A; Bokemeyer C; Bandak M; Jandari A; Collette L; Gillessen S; Beyer J; Daugaard G
    Br J Cancer; 2023 Nov; 129(11):1759-1765. PubMed ID: 37777577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excellent survival in relapsed stage I testicular cancer.
    Speicher P; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Beyer J; Akhoundova D
    BMC Cancer; 2023 Sep; 23(1):870. PubMed ID: 37715132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
    Bührer E; D'Haese D; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Collette L; Gillessen S; Beyer J
    Eur J Cancer; 2024 May; 202():114042. PubMed ID: 38564927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes of De Novo Versus Relapsed Early Metastatic Testicular Seminoma Treated With Contemporary Radiation Therapy.
    Rosen DB; Ghosh A; Niemierko A; Beard CJ; Ravi P; Tewari A; Sweeney C; Lee RJ; Saylor P; Martin N; Efstathiou JA; Mouw K; Kamran SC
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):706-711. PubMed ID: 37717783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance.
    Kollmannsberger C; Tandstad T; Bedard PL; Cohn-Cedermark G; Chung PW; Jewett MA; Powles T; Warde PR; Daneshmand S; Protheroe A; Tyldesley S; Black PC; Chi K; So AI; Moore MJ; Nichols CR
    J Clin Oncol; 2015 Jan; 33(1):51-7. PubMed ID: 25135991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of clinical stage I testicular seminoma: active surveillance versus adjuvant chemotherapy.
    Ondrusova M; Ondrus D; Miskovska V; Kajo K; Szoldova K; Usakova V; Stastna V
    Int Urol Nephrol; 2015 Jul; 47(7):1143-7. PubMed ID: 25982582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Survival in Poor Prognosis Metastatic Germ Cell Cancer in Belarus.
    Rolevich AI; Borodin DM; Rabcheuski AN; Ivanitskaya TA; Semenov SA; Artsiushkevich LV; Sukalinskaya AV; Zhavrid EA; Krasny SA; Konoplya NE; Polyakov SL
    JCO Glob Oncol; 2021 Jan; 7():63-71. PubMed ID: 33434070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer.
    Incesu RB; Morra S; Scheipner L; Barletta F; Baudo A; Garcia CC; Tappero S; Piccinelli ML; Tian Z; Saad F; Shariat SF; de Cobelli O; Terrone C; Chun FKH; Carmignani L; Briganti A; Ahyai S; Longo N; Tilki D; Graefen M; Karakiewicz PI
    Jpn J Clin Oncol; 2024 May; 54(5):592-598. PubMed ID: 38369557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer.
    Nayan M; Jewett MA; Hosni A; Anson-Cartwright L; Bedard PL; Moore M; Hansen AR; Chung P; Warde P; Sweet J; O'Malley M; Atenafu EG; Hamilton RJ
    Eur Urol; 2017 Jan; 71(1):120-127. PubMed ID: 27527805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
    Gillessen S; Sauvé N; Collette L; Daugaard G; de Wit R; Albany C; Tryakin A; Fizazi K; Stahl O; Gietema JA; De Giorgi U; Cafferty FH; Hansen AR; Tandstad T; Huddart RA; Necchi A; Sweeney CJ; Garcia-Del-Muro X; Heng DYC; Lorch A; Chovanec M; Winquist E; Grimison P; Feldman DR; Terbuch A; Hentrich M; Bokemeyer C; Negaard H; Fankhauser C; Shamash J; Vaughn DJ; Sternberg CN; Heidenreich A; Beyer J;
    J Clin Oncol; 2021 May; 39(14):1563-1574. PubMed ID: 33822655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.
    Oing C; Oechsle K; Necchi A; Loriot Y; De Giorgi U; Fléchon A; Daugaard G; Fedyanin M; Faré E; Bokemeyer C
    Ann Oncol; 2017 Mar; 28(3):576-582. PubMed ID: 27993806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance Oral Etoposide After High-Dose Chemotherapy (HDCT) for Patients With Relapsed Metastatic Germ-Cell Tumors (mGCT).
    Taza F; Abonour R; Zaid MA; Althouse SK; Anouti B; Akel R; Hanna NH; Adra N; Einhorn LH
    Clin Genitourin Cancer; 2023 Apr; 21(2):213-220. PubMed ID: 36737276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium.
    Beyer J; Collette L; Sauvé N; Daugaard G; Feldman DR; Tandstad T; Tryakin A; Stahl O; Gonzalez-Billalabeitia E; De Giorgi U; Culine S; de Wit R; Hansen AR; Bebek M; Terbuch A; Albany C; Hentrich M; Gietema JA; Negaard H; Huddart RA; Lorch A; Cafferty FH; Heng DYC; Sweeney CJ; Winquist E; Chovanec M; Fankhauser C; Stark D; Grimison P; Necchi A; Tran B; Heidenreich A; Shamash J; Sternberg CN; Vaughn DJ; Duran I; Bokemeyer C; Patrikidou A; Cathomas R; Assele S; Gillessen S;
    J Clin Oncol; 2021 May; 39(14):1553-1562. PubMed ID: 33729863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer.
    Ribnikar D; Stukalin I; Bedard PL; Hamilton RJ; Jewett M; Warde P; Chung P; Anson-Cartwright L; Templeton AJ; Amir E; Hansen AR; Heng DYC; Lewin J
    Curr Oncol; 2020 Dec; 28(1):107-114. PubMed ID: 33622996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer.
    Escudero-Ávila R; Rodríguez-Castaño JD; Osman I; Fernandez F; Medina R; Vargas B; Japón-Rodríguez M; Sancho P; Perez-Valderrama B; Praena-Fernández JM; Duran I
    Clin Transl Oncol; 2019 Jun; 21(6):796-804. PubMed ID: 30470992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late Relapse of Germ Cell Tumors After Prior Chemotherapy or Surgery-only.
    Richardson NH; Althouse SK; Ashkar R; Cary C; Masterson T; Foster RS; Einhorn LH; Adra N
    Clin Genitourin Cancer; 2023 Aug; 21(4):467-474. PubMed ID: 37088659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human chorionic gonadotropin-positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3).
    Seidel C; Daugaard G; Nestler T; Tryakin A; Fedyanin M; Fankhauser C; Hermanns T; Aparicio J; Heinzelbecker J; Paffenholz P; Heidenreich A; De Giorgi U; Cathomas R; Lorch A; Fingerhut A; Gayer F; Bremmer F; Giannatempo P; Necchi A; Aurilio G; Casadei C; Tran B; Dieckmann KP; Brito M; Ruf C; Oing C; Bokemeyer C
    Eur J Cancer; 2020 Jun; 132():127-135. PubMed ID: 32361383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options.
    Francis R; Bower M; Brunström G; Holden L; Newlands ES; Rustin GJ; Seckl MJ
    Eur J Cancer; 2000 Oct; 36(15):1925-32. PubMed ID: 11000572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.
    Antonelli L; Ardizzone D; Ravi P; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Fizazi K; King JM; Adra N; Douglawi A; Cary C; Sweeney C; Fankhauser CD
    Eur J Cancer; 2023 Mar; 182():144-154. PubMed ID: 36787661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.
    Fischer S; Tandstad T; Cohn-Cedermark G; Thibault C; Vincenzi B; Klingbiel D; Albany C; Necchi A; Terbuch A; Lorch A; Aparicio J; Heidenreich A; Hentrich M; Wheater M; Langberg CW; Ståhl O; Fankhauser CD; Hamid AA; Koutsoukos K; Shamash J; White J; Bokemeyer C; Beyer J; Gillessen S;
    J Clin Oncol; 2020 Apr; 38(12):1322-1331. PubMed ID: 31877087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.